5-(3-Methyl-1-triazeno)imidazole-4-carboxamide (BioDeep_00000011070)
Secondary id: BioDeep_00001875171
human metabolite blood metabolite
代谢物信息卡片
化学式: C5H8N6O (168.076)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 93.18%
分子结构信息
SMILES: CN=NNC1=C(NC=N1)C(=O)N
InChI: InChI=1S/C5H8N6O/c1-7-11-10-5-3(4(6)12)8-2-9-5/h2H,1H3,(H2,6,12)(H,7,10)(H,8,9)
描述信息
D009676 - Noxae > D000477 - Alkylating Agents
同义名列表
11 个代谢物同义名
5-(3-Methyl-1-triazeno)imidazole-4-carboxamide monohydrochloride; 4-(3-methyltriaz-2-en-1-yl)-1H-imidazole-5-carboxamide; 5-(3-methyltriaz-2-en-1-yl)-3H-imidazole-4-carboxamide; 5-(3-Monomethyl-1-triazeno)imidazole-4-carboxamide; 5-(3-Methyltriazen-1-yl)imidazole-4-carboxamide; 5-(3-Methyl-1-triazeno)imidazole-4-carboxamide; 5-Monomethyltriazenoimidazole-4-carboxamide; NSC-407347; NSC 407347; MTIC; MTIC
数据库引用编号
12 个数据库交叉引用编号
- ChEBI: CHEBI:72568
- KEGG: C16250
- PubChem: 76953
- HMDB: HMDB0254938
- Metlin: METLIN628
- ChEMBL: CHEMBL1442
- chemspider: 20126985
- CAS: 3413-72-7
- PMhub: MS000025008
- PubChem: 47205558
- NIKKAJI: J54.029C
- KNApSAcK: 72568
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Maria João Ramalho, Stéphanie Andrade, Manuel Álvaro Neto Coelho, Joana Angélica Loureiro, Maria Carmo Pereira. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2019 Mar; 136(?):156-163. doi:
10.1016/j.ejpb.2019.01.015. [PMID: 30682492] - Tomokazu Aoki, Ryo Nishikawa, Tomohiko Mizutani, Kuniharu Nojima, Kazuhiko Mishima, Jyunichi Adachi, Masao Matsutani. Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
International journal of clinical oncology.
2007 Oct; 12(5):341-9. doi:
10.1007/s10147-007-0687-5. [PMID: 17929115] - L Reyderman, P Statkevich, C M Thonoor, J Patrick, V K Batra, M Wirth. Disposition and pharmacokinetics of temozolomide in rat.
Xenobiotica; the fate of foreign compounds in biological systems.
2004 May; 34(5):487-500. doi:
10.1080/00498250410001685737. [PMID: 15370964] - John C Panetta, Mark N Kirstein, Amar Gajjar, Geeta Nair, Maryam Fouladi, Richard L Heideman, Mark Wilkinson, Clinton F Stewart. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
Cancer chemotherapy and pharmacology.
2003 Dec; 52(6):435-41. doi:
10.1007/s00280-003-0670-4. [PMID: 13680158] - J Ma, S Pulfer, S Li, J Chu, K Reed, J M Gallo. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
Cancer research.
2001 Jul; 61(14):5491-8. doi:
. [PMID: 11454697] - S L Safgren, J M Reid, R Rios, M M Ames. Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide.
Journal of chromatography. B, Biomedical sciences and applications.
2001 Apr; 754(1):91-6. doi:
10.1016/s0378-4347(00)00586-7. [PMID: 11318431] - S L Matheson, J McNamee, B J Jean-Claude. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy.
The Journal of pharmacology and experimental therapeutics.
2001 Mar; 296(3):832-40. doi:
. [PMID: 11181914] - D S Middlemas, C F Stewart, M N Kirstein, C Poquette, H S Friedman, P J Houghton, T P Brent. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2000 Mar; 6(3):998-1007. doi:
NULL. [PMID: 10741727] - S K Chowdhury, D Laudicina, N Blumenkrantz, M Wirth, K B Alton. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma.
Journal of pharmaceutical and biomedical analysis.
1999 Apr; 19(5):659-68. doi:
10.1016/s0731-7085(98)00198-8. [PMID: 10698531] - S D Baker, M Wirth, P Statkevich, P Reidenberg, K Alton, S E Sartorius, M Dugan, D Cutler, V Batra, L B Grochow, R C Donehower, E K Rowinsky. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1999 Feb; 5(2):309-17. doi:
. [PMID: 10037179] - J M Reid, D C Stevens, J Rubin, M M Ames. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1997 Dec; 3(12 Pt 1):2393-8. doi:
. [PMID: 9815639] - F Delben, S Paoletti, G Manzini, C Nisi. Influence of serum albumins on decomposition rates of para-substituted 1-phenyl-3-methyltriazenes and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide in near physiological conditions.
Journal of pharmaceutical sciences.
1981 Aug; 70(8):892-7. doi:
10.1002/jps.2600700815. [PMID: 7310657]
